Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program
Pediatric Blood & Cancer2008Vol. 51(1), pp. 42–48
Citations Over TimeTop 10% of 2008 papers
John M. Maris, Joshua Courtright, Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard B. Lock, Mayamin Tajbakhsh, C. Patrick Reynolds, Stephen T. Keir, Jianrong Wu, Malcolm A. Smith
Abstract
Sunitinib demonstrated significant tumor growth inhibition against most of the PPTP's solid tumor panels, but little activity against the neuroblastoma and ALL panel. Antitumor activity was manifested primarily as tumor growth delay, consistent with an anti-angiogenic effect for sunitinib against many of the pediatric preclinical models evaluated. Pediatr Blood Cancer 2008;51:42-48. (c) 2008 Wiley-Liss, Inc.
Related Papers
- → Intrarenal neuroblastoma masquerading as wilms' tumor(1998)21 cited
- → All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor(2001)38 cited
- → Aggressive neuroblastoma simulating Wilms tumor.(1988)31 cited
- → Wilms' tumor versus neuroblastoma: usefulness of ultrasound in differentiation.(1982)23 cited
- → Rhabdomyosarcoma mimicking Wilms' tumor(1994)2 cited